US › Healthcare

Rallybio Corp (RLYB)

US · Healthcare · Biotechnology

$15.96+0.06%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$212,000
Revenue YoY
0.0%
Net profit
$-8.3M
Profit YoY
+12.3%
EPS
$-1.46
EPS estimate
$-1.20
Net margin
-3,904.7%

EPS came in at -1.46 against a street estimate of -1.20 — a miss of 21.7%.

Key statistics

Market cap
$84.5M
Forward P/E
0.0
P/B
1.68
Book value
$9.50
EPS (TTM)
$-1.36
52-week high
$17.57
52-week low
$3.20
50-day MA
$15.88
200-day MA
$9.29
Beta
-0.89

Analyst view

Analysts rate Rallybio Corp a buy (1 buy, 3 hold, 0 sell out of 4) with an average price target of $8.00.

Shareholding

Insiders
4.22%
Institutions
106.84%

Largest institutional holders

FundStake
FMR Inc14.95%
Viking Global Investors LP9.88%
Cormorant Asset Management, LLC7.54%
TPG GP A, LLC7.13%
Balyasny Asset Management LLC7.10%
LAURION CAPITAL MANAGEMENT LP5.71%
Nantahala Capital Management, LLC5.67%
Pivotal bioVenture Partners Investment Advisor LLC5.66%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Rallybio Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.